Single-arm phase 2 study | Long-term follow-up of combination of B-Cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma.
9 Aug, 2022 | 12:22h | UTCLong-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
? Combination of anti-BCMA and anti-CD19 CAR T cells induced durable response in patients with relapsed/refractory #MultipleMyeloma ➡️ https://t.co/TkPRcTKSxg #JCO #MMSM pic.twitter.com/0OZAJtTXF1
— Journal of Clinical Oncology (@JCO_ASCO) April 15, 2022